Novanta ( (NOVT) ) has released its Q3 earnings. Here is a breakdown of the information Novanta presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Novanta Inc. is a leading global supplier of core technology solutions, specializing in precision medicine, precision manufacturing, robotics, automation, and advanced surgery for medical and advanced technology equipment manufacturers. In its third-quarter 2025 financial report, Novanta announced a 1.4% increase in GAAP revenue to $247.8 million and a GAAP net income of $10.7 million. The company also reported a GAAP diluted earnings per share of $0.30 and an adjusted EBITDA of $58.1 million. Despite the slight revenue growth, Novanta experienced a decline in GAAP operating income and net income compared to the previous year. The company attributed its revenue growth to acquisition activities and favorable foreign currency exchange rates, although organic revenue growth showed a decline. Novanta’s management highlighted significant growth in its Advanced Surgery business and expressed confidence in achieving financial objectives for the full year, expecting mid to high single-digit organic growth and solid double-digit adjusted EPS growth in the fourth quarter. Looking ahead, Novanta anticipates continued momentum in its business and end markets, driven by new product launches and design wins, projecting mid-single-digit organic revenue growth for the full year 2026.